Why the study?
Does amlodipine-based antihypertensive and lipid-lowering therapy reduce mortality and cardiovascular events compared to atenolol in patients with hypertension and high cardiovascular risk over a 20-year follow-up?
Does amlodipine-based antihypertensive and lipid-lowering therapy reduce mortality and cardiovascular events compared to atenolol in patients with hypertension and high cardiovascular risk over a 20-year follow-up?
Answers are grounded in this paper and cite their sources.
Amlodipine-based antihypertensive therapy combined with lipid-lowering therapy provides long-term reductions in cardiovascular events and mortality compared to atenolol in high-risk hypertensive patients.
The article presents the results of a 20-year follow-up of patients in the ASCOT Legacy study, indicating that antihypertensive and lipid-lowering therapy reduces mortality in patients with hypertension and high cardiovascular risk in the long term. In the group of patients treated with amlodipine compared with the β-blocker atenolol, there was a decrease in mean systolic and diastolic blood pressure (BP), as well as a long-term improve in the form of a decrease in the prevalence of cardiovascular events and mortality due to stroke. An important feature of therapy based on amlodipine was the reduction in BP variability. The article reflects the results of major studies that determine the possibility and effectiveness of early prescription of combined antihypertensive and lipid-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Nagorny et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: